Souhaitez-vous accéder aux communiqués récents ?

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low...

VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery,...

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral...

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company),...

Company strengthens its late-stage trials with enhanced clinical and commercial leadership for its BPM31510 programs

BOSTON and SHANGHAI, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Eccogene, a clinical-stage biopharmaceutical company developing next-generation oral small molecule therapeutics for chronic cardiometabolic...

An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metricsOV329 matched or exceeded inhibition demonstrated by...

New York, USA, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Global General Surgery Devices Market to Register Sustainable Growth at a CAGR of ~6% by 2032 | DelveInsight The general surgery devices market is...

Austin, TX, USA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Left Ventricular Assist Devices Market Size, Trends and Insights By Product...

Ottawa, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The global pain management devices market size was valued at USD 7.68 billion in 2024 and is predicted to hit around USD 19.1 billion by 2034, rising at a...